Reported 1 day ago
Gilead Sciences, Inc. (NASDAQ:GILD) is highlighted as a strong dividend stock for income investors in the pharmaceutical sector, particularly after gaining prominence with its COVID-19 antiviral treatment, remdesivir. Despite a ten-year lagging performance in the broader market, Gilead's stable cash position, generating $1.8 billion in cash flow and returning $1 billion to investors in dividends during Q1 2025, positions it well with a current dividend yield of 2.90%. The company has consistently raised dividends since 2015, appealing to income-focused investors.
Source: YAHOO